10-Q: Zomedica Q3 2025: Revenue Growth Amidst Impairment Charges

Zomedica Corp. reported increased revenue for Q3 2025 and the nine months ended September 30, 2025, despite significant impairment charges totaling $55.8 million.

Summary

• Net revenue for the three months ended September 30, 2025, increased by 16% to $8,095 thousand from $6,997 thousand in the prior year period.
• Net revenue for the nine months ended September 30, 2025, increased by 11% to $21,559 thousand from $19,390 thousand in the prior year period.
• Gross profit margin decreased to 67% for both the three and nine months ended September 30, 2025, compared to 72% and 70% respectively in 2024.
• A significant impairment expense of $55,833 thousand was recorded for the nine months ended September 30, 2025, primarily due to a decline in market capitalization following the delisting from NYSE American.
• This impairment included $45,555 thousand for goodwill, $8,297 thousand for amortizable intangible assets, and $1,981 thousand for property and equipment.
• Net loss for the nine months ended September 30, 2025, increased by 94% to $77,328 thousand from $39,788 thousand in the prior year period.
• Cash used in operating activities decreased by 12% to $16,750 thousand for the nine months ended September 30, 2025.
• A new reportable segment, "Development Services," commenced in Q3 2025, contributing $662 thousand in revenue for the nine months ended September 30, 2025.
• The company holds a 19.50% equity stake in Brisby Inc. and has made $1,611 thousand in cash payments for milestones under a development and license agreement.
• A License and Supply Agreement with Cresilon, Inc. was entered into on December 30, 2024, for VETIGEL Hemostatic Gel and related products.

Sentiment

Score: 3

Explanation: While Zomedica reported revenue growth in Q3 and year-to-date 2025, this positive was overshadowed by substantial impairment charges totaling $55.8 million, leading to a 94% increase in net loss for the nine-month period. The decline in gross profit margin and the delisting from NYSE American are significant concerns, indicating underlying operational and market valuation challenges despite management's optimistic outlook on future revenue.

Positives

• Net revenue increased by 16% to $8,095 thousand for the three months ended September 30, 2025, and by 11% to $21,559 thousand for the nine months ended September 30, 2025.
• Growth in TRUFORMA products, including the impact of launching new assays, contributed to increased revenue.
• Consumables sales for existing PulseVet and Assisi products showed growth.
• Sales from VETIGEL products, which the company began to market and sell, contributed to revenue.
• The new Development Services segment generated $662 thousand in revenue for the nine months ended September 30, 2025.
• General and administrative expenses decreased by 13% for the three months and 22% for the nine months ended September 30, 2025, primarily due to reduced professional fees and one-time costs.
• Net cash used in operating activities decreased by 12% to $16,750 thousand for the nine months ended September 30, 2025.
• Net cash provided by investing activities increased by 7% to $17,126 thousand for the nine months ended September 30, 2025, driven by decreased capital expenditures and investments in nonconsolidated entities.
• Management believes existing cash is sufficient to fund both short-term and long-term operational requirements.

Negatives

• A significant impairment expense of $55,833 thousand was recorded for the nine months ended September 30, 2025, primarily due to a decline in market capitalization following the delisting from NYSE American.
• Net loss for the nine months ended September 30, 2025, increased by 94% to $77,328 thousand, compared to $39,788 thousand in the prior year period.
• Gross profit margin decreased to 67% for both the three and nine months ended September 30, 2025, from 72% and 70% respectively in 2024, due to higher depreciation and product mix changes.
• The accumulated deficit increased to $295,243 thousand as of September 30, 2025.
• The company expects to continue recording net losses in future periods until sufficient revenue from product sales offsets operating expenses.
• Total assets decreased from $207,360 thousand at December 31, 2024, to $130,905 thousand at September 30, 2025, largely due to impairment charges.
• Total shareholders' equity decreased from $195,664 thousand at December 31, 2024, to $119,688 thousand at September 30, 2025.

Risks

• Adverse macroeconomic conditions could negatively impact business operations and financial performance.
• Geopolitical tensions may disrupt global markets and supply chains.
• Changes in laws and policies resulting from federal government administration changes could affect the company.
• The impact of trade tariffs may increase costs and reduce profitability.
• Changes in consumer confidence and spending in response to economic volatility could reduce demand for products.
• The ability to develop and commercialize products successfully is crucial for future growth.
• Challenges in successfully integrating acquisitions into the business could hinder performance.
• Supply chain disruptions may increase costs and impair the ability to manufacture products.
• The ability to attract and retain senior management and key scientific personnel is vital for innovation and operations.
• Obtaining and maintaining intellectual property protection is essential for competitive advantage.
• The accuracy of estimates regarding expenses, future revenues, and capital requirements may impact financial projections.
• There is a risk of loss if customers return TRUFORMA capital and discontinue consumable or related service purchases, as customers are not obligated to purchase the capital.
• Changes in assumptions concerning future financial performance, increases in discount rates, or other market and operational factors could negatively impact the recoverability of amortizable intangible assets or property and equipment, potentially requiring additional impairment charges.
• Volatility in the company's stock price may lead to fluctuations in recognized compensation expense and recorded liability for cash-settled Stock Appreciation Rights (SARs).
• Due to historical losses, there is uncertainty in realizing tax benefits, necessitating a full valuation allowance against Canadian deferred tax assets.
• Climate change may impact operations, customer needs, operating costs, and the demand, price, and availability of property and casualty insurance.

Future Outlook

Management expects revenue to increase in subsequent periods as sales, marketing, and commercialization efforts are expanded. Research and development expenses are anticipated to continue increasing to maintain and enhance current product lines and develop new products. Selling and marketing expenses are also expected to rise in line with product expansion and commercialization growth. The company anticipates recording net losses in future periods until product sales revenue is sufficient to offset operating expenses. Management believes existing cash is sufficient to fund both short-term and long-term operational requirements.

Management Comments

• We expect revenue to increase in subsequent periods as we increase our sales, marketing, and commercialization efforts.
• We anticipate that costs of revenue will continue to increase in subsequent periods in accordance with increased unit sales.
• While we expect future general and administrative expense to increase, we expect it to decrease proportionally relative to sales and related product expansion.
• We anticipate that research and development expense will continue to increase as we maintain and enhance our current product lines and develop new products.
• We expect future selling and marketing expense to increase in line with product expansion and growth in our commercialization efforts.
• We expect to continue to record net losses in future periods until such time as we have sufficient revenue from product sales to offset our operating expenses.
• We believe that our existing cash is sufficient to fund our expected short-term needs (defined as the next 12 months).
• We believe that our existing cash resources will be sufficient to fund our expected operational requirements for the long-term period (defined as beyond the next twelve months).

Industry Context

The veterinary health industry continues to see demand for diagnostic and therapeutic products for companion animals. Zomedica's focus on unmet needs and expansion into new product lines like VETIGEL and Development Services aligns with market trends for innovation and diversified offerings. However, the company operates in a competitive landscape, and its ability to successfully commercialize new products and integrate acquisitions will be crucial for sustained growth. The significant impairment charges reflect challenges in market valuation and the need for effective integration and performance of acquired assets.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders face significant dilution risk if additional equity is issued and have experienced a substantial decline in market capitalization and share price, leading to delisting from NYSE American. Increased net loss and accumulated deficit negatively impact shareholder value.
• Employees are incentivized through stock-based compensation plans (stock options, SARs).
• Customers benefit from new products (VETIGEL, new TRUFORMA assays) and expanded Development Services offerings. However, the risk of capital returns for TRUFORMA instruments could impact service continuity.
• Creditors' position is influenced by the company's liquidity, which, while deemed sufficient by management for short-term and long-term needs, is affected by ongoing losses and a declining asset base.

Next Steps

• Increase sales, marketing, and commercialization efforts to drive revenue growth.
• Maintain and enhance current product lines and develop new therapeutic and diagnostic products.
• Continue to assess the commercialization status and relationships with companies for indefinite-lived licenses and adjust amortization schedules accordingly.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2025-06, ASU 2024-03, ASU 2023-09) on consolidated financial statements.

Key Dates

Recommendation

Despite revenue growth, the company reported a substantial increase in net loss for the nine months ended September 30, 2025, primarily driven by over $55 million in impairment charges related to goodwill, intangible assets, and property and equipment. This impairment was triggered by a significant decline in market capitalization following the delisting from NYSE American. The gross profit margin also decreased. While management expresses confidence in long-term liquidity, the ongoing net losses, significant asset write-downs, and the delisting event signal fundamental challenges and a deteriorating financial position, making the stock a high-risk investment with significant downside potential.

Keywords

Veterinary Health, Pet Care, Diagnostics, Therapeutics, Animal Health, SEC Filing, Zomedica, TRUFORMA, PulseVet, VETIGEL, Q3 Earnings, Financial Results, Impairment, Stock Appreciation Rights, Corporate Governance